Leonardo A. Meza-Zepeda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Leonardo A. Meza-Zepeda has a total of 338 co-authors. Here are the top co-authors by number of shared publications:
- Ola Myklebost
Department of Clinical Science, University of Bergen
32 shared publications Susanne Lorenz
10 shared publications- Eivind Hovig
Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway
9 shared publications - Susanne Lorenz
Oslo University Hospital
9 shared publications - Kjetil Boye
Department of Oncology, Oslo University Hospital, Oslo, Norway
8 shared publications Ola Myklebost
Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
8 shared publications
Latest Publications
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Validation of a Seven-Gene Predictive SIGNature for the Efficacy of Immuno-Oncology PD-1 Inhibitors in Patients with Sarcoma
Supplementary Figure S1. Correlation between the 7-gene-based signature score and best response. The test of Mann-Whitney was used for the correlation analyses.
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Validation of a Seven-Gene Predictive SIGNature for the Efficacy of Immuno-Oncology PD-1 Inhibitors in Patients with Sarcoma
Supplementary Figure S1. Correlation between the 7-gene-based signature score and best response. The test of Mann-Whitney was used for the correlation analyses.
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Validation of a Seven-Gene Predictive SIGNature for the Efficacy of Immuno-Oncology PD-1 Inhibitors in Patients with Sarcoma
Supplementary Table S3. Patient demographics of patients enrolled in the GEIS-32 clinical trial.
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Validation of a Seven-Gene Predictive SIGNature for the Efficacy of Immuno-Oncology PD-1 Inhibitors in Patients with Sarcoma
Supplementary Table S3. Patient demographics of patients enrolled in the GEIS-32 clinical trial.
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Validation of a Seven-Gene Predictive SIGNature for the Efficacy of Immuno-Oncology PD-1 Inhibitors in Patients with Sarcoma
Supplementary Table S1. MAXSTAT cut-off values for each gene of SIGNIOS signature.
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Validation of a Seven-Gene Predictive SIGNature for the Efficacy of Immuno-Oncology PD-1 Inhibitors in Patients with Sarcoma
Supplementary Table S1. MAXSTAT cut-off values for each gene of SIGNIOS signature.
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Data from Validation of a Seven-Gene Predictive SIGNature for the Efficacy of Immuno-Oncology PD-1 Inhibitors in Patients with Sarcoma
Purpose:Immune checkpoint inhibitors (ICI) have transformed cancer therapy, but their efficacy in sarcomas remains limited. A seven-gene predictive signature (CD86, CHI3L1, CXCL10, CXCL9, LAG3, NR4A1, and VCAM1) was previously identified as a biomarker for response to combined antiangiogenic and PD-1 inhibitor therapy in soft-tissue sarcomas. This study aimed to externally validate the predictive utility of this signature [SIGNature for immuno-oncology PD-1 inhibitors in sarcoma (SIGNIOS)] in an independent cohort of patients with sarcoma treated with ICIs.Experimental Design:Using RNA sequencing data from pretreatment tumor samples from the SARC028 phase II trial (pembrolizumab for advanced sarcomas) and the GEIS-32 phase II trial (pazopanib in advanced solitary fibrous tumor), we calculated the SIGNIOS score. Patients were stratified into low (score 0–4) and high (score 5–7) risk groups.Results:The SARC028 validation cohort comprised 31 patients, with a median age of 33 years, and 45.2% were female. The most common histologic subtypes included osteosarcoma (25.8%) and Ewing sarcoma (19.4%). The seven-gene signature significantly stratified patients into groups with significantly different progression-free survival (PFS): Those with scores of 0 to 4 had a median PFS of 49 days, whereas those with scores of 5 to 7 had a median PFS of 170 days [HR = 0.71 (95% confidence interval, 0.55–0.91), P = 0.007].Conclusions:This external validation confirms the seven-gene signature as a potential biomarker for predicting ICI efficacy in advanced sarcomas. Prospective studies are needed to determine the prognostic versus predictive value of SIGNIOS, refine its use across sarcoma subtypes, and explore its applicability in other tumor types.
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Validation of a Seven-Gene Predictive SIGNature for the Efficacy of Immuno-Oncology PD-1 Inhibitors in Patients with Sarcoma
Purpose:Immune checkpoint inhibitors (ICI) have transformed cancer therapy, but their efficacy in sarcomas remains limited. A seven-gene predictive signature (CD86, CHI3L1, CXCL10, CXCL9, LAG3, NR4A1, and VCAM1) was previously identified as a biomarker for response to combined antiangiogenic and PD-1 inhibitor therapy in soft-tissue sarcomas. This study aimed to externally validate the predictive utility of this signature [SIGNature for immuno-oncology PD-1 inhibitors in sarcoma (SIGNIOS)] in an independent cohort of patients with sarcoma treated with ICIs.Experimental Design:Using RNA sequencing data from pretreatment tumor samples from the SARC028 phase II trial (pembrolizumab for advanced sarcomas) and the GEIS-32 phase II trial (pazopanib in advanced solitary fibrous tumor), we calculated the SIGNIOS score. Patients were stratified into low (score 0–4) and high (score 5–7) risk groups.Results:The SARC028 validation cohort comprised 31 patients, with a median age of 33 years, and 45.2% were female. The most common histologic subtypes included osteosarcoma (25.8%) and Ewing sarcoma (19.4%). The seven-gene signature significantly stratified patients into groups with significantly different progression-free survival (PFS): Those with scores of 0 to 4 had a median PFS of 49 days, whereas those with scores of 5 to 7 had a median PFS of 170 days [HR = 0.71 (95% confidence interval, 0.55–0.91), P = 0.007].Conclusions:This external validation confirms the seven-gene signature as a potential biomarker for predicting ICI efficacy in advanced sarcomas. Prospective studies are needed to determine the prognostic versus predictive value of SIGNIOS, refine its use across sarcoma subtypes, and explore its applicability in other tumor types.
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Validation of a Seven-Gene Predictive SIGNature for the Efficacy of Immuno-Oncology PD-1 Inhibitors in Patients with Sarcoma
Supplementary Table S2 – Univariate survival analysis of the genes included in the 7-gene-based signature score.
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Validation of a Seven-Gene Predictive SIGNature for the Efficacy of Immuno-Oncology PD-1 Inhibitors in Patients with Sarcoma
Supplementary Table S2 – Univariate survival analysis of the genes included in the 7-gene-based signature score.
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Validation of a Seven-Gene Predictive SIGNature for the Efficacy of Immuno-Oncology PD-1 Inhibitors in Patients with Sarcoma
Supplementary Figure S2. Progression-free survival probability of the patients treated within the GEIS-32 clinical trial, according to the 7 gene-based score. Time is defined in months.
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Validation of a Seven-Gene Predictive SIGNature for the Efficacy of Immuno-Oncology PD-1 Inhibitors in Patients with Sarcoma
Supplementary Figure S2. Progression-free survival probability of the patients treated within the GEIS-32 clinical trial, according to the 7 gene-based score. Time is defined in months.
- 15 January 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (7) , 1258-1265
Validation of a Seven-Gene Predictive SIGNature for the Efficacy of Immuno-Oncology PD-1 Inhibitors in Patients with Sarcoma
Purpose: Immune checkpoint inhibitors (ICI) have transformed cancer therapy, but their efficacy in sarcomas remains limited. A seven-gene predictive signature (CD86, CHI3L1, CXCL10, CXCL9, LAG3, NR4A1, and VCAM1) was previously identified as a biomarker for response to combined antiangiogenic and PD-1 inhibitor therapy in soft-tissue sarcomas. This study aimed to externally validate the predictive utility of this signature [SIGNature for immuno-oncology PD-1 inhibitors in sarcoma (SIGNIOS)] in an independent cohort of patients with sarcoma treated with ICIs. Experimental Design: Using RNA sequencing data from pretreatment tumor samples from the SARC028 phase II trial (pembrolizumab for advanced sarcomas) and the GEIS-32 phase II trial (pazopanib in advanced solitary fibrous tumor), we calculated the SIGNIOS score. Patients were stratified into low (score 0–4) and high (score 5–7) risk groups. Results: The SARC028 validation cohort comprised 31 patients, with a median age of 33 years, and 45.2% were female. The most common histologic subtypes included osteosarcoma (25.8%) and Ewing sarcoma (19.4%). The seven-gene signature significantly stratified patients into groups with significantly different progression-free survival (PFS): Those with scores of 0 to 4 had a median PFS of 49 days, whereas those with scores of 5 to 7 had a median PFS of 170 days [HR = 0.71 (95% confidence interval, 0.55–0.91), P = 0.007]. Conclusions: This external validation confirms the seven-gene signature as a potential biomarker for predicting ICI efficacy in advanced sarcomas. Prospective studies are needed to determine the prognostic versus predictive value of SIGNIOS, refine its use across sarcoma subtypes, and explore its applicability in other tumor types.
- 15 January 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (7) , 1258-1265
Validation of a Seven-Gene Predictive SIGNature for the Efficacy of Immuno-Oncology PD-1 Inhibitors in Patients with Sarcoma
Purpose: Immune checkpoint inhibitors (ICI) have transformed cancer therapy, but their efficacy in sarcomas remains limited. A seven-gene predictive signature (CD86, CHI3L1, CXCL10, CXCL9, LAG3, NR4A1, and VCAM1) was previously identified as a biomarker for response to combined antiangiogenic and PD-1 inhibitor therapy in soft-tissue sarcomas. This study aimed to externally validate the predictive utility of this signature [SIGNature for immuno-oncology PD-1 inhibitors in sarcoma (SIGNIOS)] in an independent cohort of patients with sarcoma treated with ICIs. Experimental Design: Using RNA sequencing data from pretreatment tumor samples from the SARC028 phase II trial (pembrolizumab for advanced sarcomas) and the GEIS-32 phase II trial (pazopanib in advanced solitary fibrous tumor), we calculated the SIGNIOS score. Patients were stratified into low (score 0–4) and high (score 5–7) risk groups. Results: The SARC028 validation cohort comprised 31 patients, with a median age of 33 years, and 45.2% were female. The most common histologic subtypes included osteosarcoma (25.8%) and Ewing sarcoma (19.4%). The seven-gene signature significantly stratified patients into groups with significantly different progression-free survival (PFS): Those with scores of 0 to 4 had a median PFS of 49 days, whereas those with scores of 5 to 7 had a median PFS of 170 days [HR = 0.71 (95% confidence interval, 0.55–0.91), P = 0.007]. Conclusions: This external validation confirms the seven-gene signature as a potential biomarker for predicting ICI efficacy in advanced sarcomas. Prospective studies are needed to determine the prognostic versus predictive value of SIGNIOS, refine its use across sarcoma subtypes, and explore its applicability in other tumor types.
- Open Access
- 4 January 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (3)
Evolutionary mode and timing of dissemination of high-grade serous carcinomas
Dissemination within the peritoneal cavity is a main determinant of poor patient outcomes from high-grade serous carcinomas (HGSCs). The dissemination process is poorly understood from a cancer evolutionary perspective. We reconstructed the evolutionary trajectories across a median of 5 tumor sites and regions from each of 23 patients based on deep whole-exome sequencing. Polyclonal cancer origin was detected in 1 patient. Ovarian tumors had more complex subclonal architectures than other intraperitoneal tumors in each patient, which indicated that tumors developed earlier in the ovaries. Three common modes of dissemination were identified, including monoclonal or polyclonal dissemination of monophyletic (linear) or polyphyletic (branched) subclones. Mutation profiles of initial or disseminated clones varied greatly among cancers, but recurrent mutations were found in 7 cancer-critical genes, including TP53 , BRCA1 , BRCA2 , and DNMT3A , and in the PI3K/AKT1 pathway. Disseminated clones developed late in the evolutionary trajectory models of most cancers, in particular in cancers with DNA damage repair deficiency. Polyclonal dissemination was predicted to occur predominantly as a single and rapid wave, but chemotherapy exposure was associated with higher genomic diversity of disseminated clones. In conclusion, we described three common evolutionary dissemination modes across HGSCs and proposed factors associated with dissemination diversity.
- 4 January 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (3)
Open AccessEvolutionary mode and timing of dissemination of high-grade serous carcinomas
Dissemination within the peritoneal cavity is a main determinant of poor patient outcomes from high-grade serous carcinomas (HGSCs). The dissemination process is poorly understood from a cancer evolutionary perspective. We reconstructed the evolutionary trajectories across a median of 5 tumor sites and regions from each of 23 patients based on deep whole-exome sequencing. Polyclonal cancer origin was detected in 1 patient. Ovarian tumors had more complex subclonal architectures than other intraperitoneal tumors in each patient, which indicated that tumors developed earlier in the ovaries. Three common modes of dissemination were identified, including monoclonal or polyclonal dissemination of monophyletic (linear) or polyphyletic (branched) subclones. Mutation profiles of initial or disseminated clones varied greatly among cancers, but recurrent mutations were found in 7 cancer-critical genes, including TP53 , BRCA1 , BRCA2 , and DNMT3A , and in the PI3K/AKT1 pathway. Disseminated clones developed late in the evolutionary trajectory models of most cancers, in particular in cancers with DNA damage repair deficiency. Polyclonal dissemination was predicted to occur predominantly as a single and rapid wave, but chemotherapy exposure was associated with higher genomic diversity of disseminated clones. In conclusion, we described three common evolutionary dissemination modes across HGSCs and proposed factors associated with dissemination diversity.
- Open Access
- 3 September 2023
- Published by Wiley in Molecular Oncology
- Vol. 17 (11) , 2432-2450
Chromosomal instability and a deregulated cell cycle are intrinsic features of high‐risk gastrointestinal stromal tumours with a metastatic potential
Patients with localised, high‐risk gastrointestinal stromal tumours (GIST) benefit from adjuvant imatinib treatment. Still, approximately 40% of patients relapse within 3 years after adjuvant therapy and the clinical and histopathological features currently used for risk classification cannot precisely predict poor outcomes after standard treatment. This study aimed to identify genomic and transcriptomic profiles that could be associated with disease relapse and thus a more aggressive phenotype. Using a multi‐omics approach, we analysed a cohort of primary tumours from patients with untreated, resectable high‐risk GISTs. We compared patients who developed metastatic disease within 3 years after finishing adjuvant imatinib treatment and patients without disease relapse after more than 5 years of follow‐up. Combining genomics and transcriptomics data, we identified somatic mutations and deregulated mRNA and miRNA genes intrinsic to each group. Our study shows that increased chromosomal instability (CIN), including chromothripsis and deregulated kinetochore and cell cycle signalling, separates high‐risk samples according to metastatic potential. The increased CIN seems to be an intrinsic feature for tumours that metastasise and should be further validated as a novel prognostic biomarker for high‐risk GIST.
- 3 September 2023
- Published by Wiley in Molecular Oncology
- Vol. 17 (11) , 2432-2450
Open AccessChromosomal instability and a deregulated cell cycle are intrinsic features of high‐risk gastrointestinal stromal tumours with a metastatic potential
Patients with localised, high‐risk gastrointestinal stromal tumours (GIST) benefit from adjuvant imatinib treatment. Still, approximately 40% of patients relapse within 3 years after adjuvant therapy and the clinical and histopathological features currently used for risk classification cannot precisely predict poor outcomes after standard treatment. This study aimed to identify genomic and transcriptomic profiles that could be associated with disease relapse and thus a more aggressive phenotype. Using a multi‐omics approach, we analysed a cohort of primary tumours from patients with untreated, resectable high‐risk GISTs. We compared patients who developed metastatic disease within 3 years after finishing adjuvant imatinib treatment and patients without disease relapse after more than 5 years of follow‐up. Combining genomics and transcriptomics data, we identified somatic mutations and deregulated mRNA and miRNA genes intrinsic to each group. Our study shows that increased chromosomal instability (CIN), including chromothripsis and deregulated kinetochore and cell cycle signalling, separates high‐risk samples according to metastatic potential. The increased CIN seems to be an intrinsic feature for tumours that metastasise and should be further validated as a novel prognostic biomarker for high‐risk GIST.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Noninvasive Detection of ctDNA Reveals Intratumor Heterogeneity and Is Associated with Tumor Burden in Gastrointestinal Stromal Tumor
Molecular analysis of circulating tumor DNA (ctDNA) has a large potential for clinical application by capturing tumor-specific aberrations through noninvasive sampling. In gastrointestinal stromal tumor (GIST), analysis of KIT and PDGFRA mutations is important for therapeutic decisions, but the invasiveness of traditional biopsies limits the possibilities for repeated sampling. Using targeted next-generation sequencing, we have analyzed circulating cell-free DNA from 50 GIST patients. Tumor-specific mutations were detected in 16 of 44 plasma samples (36%) from treatment-naïve patients and in three of six (50%) patients treated with tyrosine kinase inhibitors. A significant association between detection of ctDNA and the modified National Institutes of Health risk classification was found. All patients with metastatic disease had detectable ctDNA, and tumor burden was the most important detection determinant. Median tumor size was 13.4 cm for patients with detectable mutation in plasma compared with 4.4 cm in patients without detectable mutation (P = 0.006). ctDNA analysis of a patient with disease progression on imatinib revealed that multiple resistance mutations were synchronously present, and detailed analysis of tumor tissue showed that these were spatially distributed in the primary tumor. Plasma samples taken throughout the course of treatment demonstrated that clonal evolution can be monitored over time. In conclusion, we have shown that detection of GIST-specific mutations in plasma is particularly feasible for patients with high tumor burden. In such cases, we have demonstrated that mutational analysis by use of liquid biopsies can capture the molecular heterogeneity of the whole tumor, and may guide treatment decisions during progression. Mol Cancer Ther; 17(11); 2473–80. ©2018 AACR.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Noninvasive Detection of ctDNA Reveals Intratumor Heterogeneity and Is Associated with Tumor Burden in Gastrointestinal Stromal Tumor
Molecular analysis of circulating tumor DNA (ctDNA) has a large potential for clinical application by capturing tumor-specific aberrations through noninvasive sampling. In gastrointestinal stromal tumor (GIST), analysis of KIT and PDGFRA mutations is important for therapeutic decisions, but the invasiveness of traditional biopsies limits the possibilities for repeated sampling. Using targeted next-generation sequencing, we have analyzed circulating cell-free DNA from 50 GIST patients. Tumor-specific mutations were detected in 16 of 44 plasma samples (36%) from treatment-naïve patients and in three of six (50%) patients treated with tyrosine kinase inhibitors. A significant association between detection of ctDNA and the modified National Institutes of Health risk classification was found. All patients with metastatic disease had detectable ctDNA, and tumor burden was the most important detection determinant. Median tumor size was 13.4 cm for patients with detectable mutation in plasma compared with 4.4 cm in patients without detectable mutation (P = 0.006). ctDNA analysis of a patient with disease progression on imatinib revealed that multiple resistance mutations were synchronously present, and detailed analysis of tumor tissue showed that these were spatially distributed in the primary tumor. Plasma samples taken throughout the course of treatment demonstrated that clonal evolution can be monitored over time. In conclusion, we have shown that detection of GIST-specific mutations in plasma is particularly feasible for patients with high tumor burden. In such cases, we have demonstrated that mutational analysis by use of liquid biopsies can capture the molecular heterogeneity of the whole tumor, and may guide treatment decisions during progression. Mol Cancer Ther; 17(11); 2473–80. ©2018 AACR.